摘要
Abstract
Objective To compare the efficacy and safety of Paclitaxel liposome + oxaliplatin + S-1 chemotherapy regi-men and Docetaxel + cisplatin + fluorouracil chemotherapy regimen(DCF)in advanced gastric cancer. Methods 45 patients with confirmed diagnosis of advanced gastric cancer by histopathological and cytological examination from January 2012-December 2013 were divided into research group and control group. The research group was given the Paclitaxel liposome + oxaliplatin +S-1 chemotherapy,and the control group had the DCF. The efficacy and toxic-side effects were compared. Results The reaction rate of study group was 40. 9%, control rate was 86. 3%, control group response rate was 38. 1%, control rate was 90. 4%, and there was no significant difference between the two groups(P>0. 05). Both the two groups were followed up for 6-23 months. The progression free time for the study group was 29 weeks,and the control group was 23 weeks. The difference between the two groups was statistically significant(P<0. 05)by Log-rank method. The percentage of III-IV degree of digestive tract reaction in the study group was 13. 6%(3/22),the control group was 42. 8%(9/21),and the difference was statistically significant(P<0. 05);the percentage of III-IV white blood cells decrease in the study group was 9%(2/22),the control group was 38. 1%(8/21),and there was significant difference between the two groups(P<0. 05);the percentage of anemia in the study group was 13. 6%(3/22),the control group was 47. 6%(10/21),the difference between the two groups was statistically significant(P<0. 05). Conclusion Paclitaxel liposome + oxaliplatin + S-1 has better curative effect and less side effects in the treatment of advanced gastric cancer, and it is worthy of further study.关键词
胃癌/紫杉醇脂质体/奥沙利铂/替吉奥/疗效/毒副反应Key words
gastric cancer/paclitaxel liposome/oxaliplatin/S-1/efficacy/toxicity分类
医药卫生
